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emphasis remains on parental involvement.
Richard C. Fulkerson, MD, Anita R. Webb, PhD,
John Peter Smith Family Medicine Residency Program, 
Fort Worth, Tex
What is the most effective
treatment for ADHD 
in children?
■ EVIDENCE-BASED ANSWER
Stimulant medication therapy is the most effec-
tive treatment for attention deficit/hyperactivity
disorder (ADHD) in children, producing 
significant improvements in symptoms and 
modest improvements in academic achievement 
(strength of recommendation [SOR]: A, based on 
multiple randomized controlled trials [RCTs]).
Nonpharmacologic therapies, such as behavior
therapy, school-based interventions, and family
therapy, are not as effective as stimulants but may
add modest benefit to the effects of medication
(SOR: B, based on 1 RCT).
While atomoxetine (Strattera) improves the
symptoms of ADHD (SOR: A, based on multiple
RCTs), stimulant medications other than
methylphenidate offer no distinct short-term
advantages (SOR: A, based on meta-analyses of
multiple RCTs). Combination drug therapies offer
no significant advantage to stimulants alone
unless a comorbid condition is present (SOR: A,
based on a meta-analysis of 20 RCTs). 
The combination of methylphenidate and cloni-
dine (Catapres) improves symptoms in children
with both ADHD and tics (SOR: B, based on 1
RCT). Clonidine is less effective alone and has 
significant side effects (SOR: B, based on a meta-
analysis of nonrandomized trials). 
■ EVIDENCE SUMMARY
In numerous systematic reviews, RCTs, and meta-
analyses, 70% of children responded to stimulant
medications with short-term improvements in
ADHD symptoms (inattention and hyperactivity/
impulsivity) and academic achievement. A forty-
year review looked at 135 trials and 413 RCTs
of methylphenidate in over 19,000 children with
an average age of 8.8 years (range, 8.3–9.4
years) for an average duration of 6 weeks
(range, 3.3–8.0 weeks).1–3
Study groups included mostly elementary
school–aged male children, with few minorities
represented. Comorbid conditions, present in
65% of children with ADHD, were often poorly
controlled. Outcome measures varied among
studies.3
The effect size from stimulant medication in
these studies averaged 0.8 for symptom relief
and between 0.4 and 0.5 for academic achieve-
ment. (Effect size is the difference between the
means of the experimental and control groups
expressed in standard deviations. An effect size
of 0.2 is considered small, 0.5 is medium, and
0.8 is considered moderate to large.)
A large randomized trial of 579 children with
ADHD (20% girls) aged 7 to 9.9 years compared
outcomes of 4 treatment strategies: stimulant
medication, intensive behavioral treatment,
combined stimulant medication and behavioral
interventions, and standard community care.4
All children met the DSM-IV criteria for ADHD
Combined Type (the most common type of
ADHD in this age group). The stimulant med-
ication strategy included an initial dose titration
period followed by monthly 30-minute visits.
Intensive behavioral treatment involved child,
parent, and school personnel components of
therapy. Combination therapy added the regi-
mens for medication and behavioral treatment
together. Standard community care consisted 
of usual (nonsystematic) care, evaluated at 
6 different sites. 
After 14 months of treatment, children in the
medication group and the combined treatment
groups showed more improvement in ADHD
symptoms than children given intensive behav-
ioral treatment or those who received standard
community care. When combined with medica-
tion, those treated with behavioral therapy
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showed slight improvement in social skills, 
anxiety, aggression, oppositional behavior, and
academic achievement over medication alone.
At the conclusion of the study, 74% of the 212
children on medication were successfully 
maintained on methylphenidate alone, 10%
required dextroamphetamine, and no children
required more than one medication. This study
found that higher doses of medication with more
frequent office follow-up and regular school 
contact were important features of successful
treatment. Only 40% of families were able to
complete the intensive behavioral therapy. 
Several short-term reviews and meta-analy-
ses show that side effects from stimulant med-
ications are mild and have short duration.5 More
long-term studies are required to evaluate
effects on growth. RCTs have limited power to
detect rare adverse events that may be better
detected by large observational studies.6
Atomoxetine, a specific norepinephrine 
reuptake inhibitor, is an FDA-approved alterna-
tive to stimulants for ADHD treatment in 
children and adolescents. Based on 3 RCTs7 of
588 children between the ages of 7 and 18
years, atomoxetine showed dose-related
improvement in ADHD rating scales. Side
Commonly used medications for ADHD
Medication Starting Maximum Monthly cost 
dose dose (generic)
Methylphenidate 5–10 mg 45 mg/d $20
2–3 times daily
Dextroamphetamine 5 mg 40 mg/d $18
1–2 times daily
Amphetamine/ 5 mg 60 mg/d $50
Dextroamphetamine 1–2 times daily
Atomoxetine 40 mg 100 mg/d $86
once daily
Common adverse drug reactions for all ADHD medications: Nervousness, insomnia, dry mouth, 
anorexia, abdominal pain, nausea, constipation, palpitations, tachycardia.
TA B L E   
effects of atomoxetine are similar to stimulants
and include mild but significant increases in
blood pressure and pulse.7
A meta-analysis of 11 non-randomized trials
using clonidine for ADHD showed a smaller
effect size compared with stimulants.8 One RCT
of 136 children with ADHD and tics showed
improvement of both problems with the use of
methylphenidate and clonidine, particularly in
combination.9 Second-line medications such as
clonidine, pemoline (Cylert), and tricyclic anti-
depressants have more potential serious side
effects and are not well studied.10
■ RECOMMENDATIONS FROM
OTHERS
The American Academy of Pediatrics recom-
mends that clinicians: 1) manage ADHD as a
chronic illness, 2) collaborate with parents, the
child, and school personnel to define specific
desired outcomes, 3) use stimulant or behav-
ioral therapy to improve these outcomes; if one
stimulant is not effective at the highest feasible
dose, try another, 4) reevaluate the diagnosis,
treatment options, adherence, and possible
coexisting conditions if treatment is not achiev-
ing the desired outcomes, and 5) follow-up 
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regularly with parents, child, and teachers to
monitor for progress and adverse effects.11
Lisa A. Johnson, MD, Providence St. Peter Hospital
Family Practice Residency, Olympia, Wash; 
Sarah Safranek, MLIS, University of Washington 
Health Sciences Library, Seattle
■ CLINICAL COMMENTARY
When patients, parents, and teachers are
educated, we achieve better outcomes
Stimulants and atomoxetine improve symp-
toms of ADHD quite effectively, making office
treatment of ADHD a gratifying experience.
Like many other diagnoses, there are numer-
ous medications available to treat ADHD.
Becoming familiar with a few and regularly
prescribing them makes the treatment of
ADHD more comfortable for the physician.
Sometimes patients and parents are hesitant
to take medication for ADHD. Education about
ADHD, along with trials of behavioral therapy,
often improves patient satisfaction and compli-
ance with medication. Likewise, children and
adolescents may resist medication because of
stigma or feeling unfairly labeled with a dis-
ease. Because of this, it is helpful to choose a
medication with a long duration, so school dos-
ing can be avoided. Artful negotiation with the
patient and parent is beneficial.
In my experience, when patients, parents,
and teachers are well-educated about ADHD
and use behavioral therapy along with med-
ication, we achieve better outcomes. Useful
information for physicians and parents
regarding medication use and behavioral
therapy are described in the American
Academy of Pediatrics ADHD Toolkit avail-
able at www.nichq.org/resources/toolkit.
Jerry Friemoth, MD, University of Cincinnati
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What is the interval 
for monitoring warfarin
therapy once therapeutic
levels are achieved?
■ EVIDENCE-BASED ANSWER
The international normalized ratio (INR) should be
measured monthly once therapeutic levels are
achieved and are stable for at least 8 weeks,
although treatment should be individualized and an
increased frequency may be required by some
patients (Table) (strength of recommendation
[SOR]: C, consensus statements). For highly com-
pliant patients with stable levels and a clear under-
standing of factors that influence anticoagulation
(changes in health, diet, medications), routine mon-
itoring may be extended to 6 weeks (SOR: B, single
randomized controlled trial [RCT]) or longer (SOR:
C, case series). Patient-managed warfarin therapy,
using biweekly self-measurements, results in more
time in therapeutic range than routine physician-
managed care (SOR: A, RCTs). 
■ EVIDENCE SUMMARY
Under- or over-treatment with warfarin can result in
life-threatening complications. Limited research
exists to guide the selection of an interval for moni-
toring anticoagulation in stabilized patients. One
RCT compared INR monitoring in an anticoagulation
clinic at 6 weeks and 4 weeks among 124 patients
with a prosthetic heart valve on stable oral antico-
agulant treatment and found no difference in throm-
boembolic or hemorrhagic events.1 A study in the
United Kingdom used a 14-week interval for select-
ed patients, but it used no comparison group.2 Kent
et al developed a computer-based model to compute
the optimum interval for monitoring anticoagulation
that considers the variability of the patient’s previ-
ous levels and costs associated with testing and
potential complications. This model achieved a max-
imum interval of 11 weeks for very stable patients.3
More frequent testing results in higher time in
therapeutic range, particularly when patients self-
monitor. A German study of 200 patients with
prosthetic heart valves found that they tested
within a therapeutic range 48% of the time when
monitored by their physician “as usual” (average
interval 24 days), and 64% of the time when the
interval was increased to 2 weeks.4 When the
same patients then went to self-monitoring every
8, 4, and 2 days, they achieved therapeutic levels
76%, 89%, and 90% of the time, respectively.
Bleeding and thromboembolic complications were
not reported, but have been demonstrated else-
where to be lower among patients who self-test
frequently (eg, twice weekly) when compared
with usual care (average interval 19 days) (4.49%
and 0.9% vs 10.9% and 3.6%; number needed to
treat [NNT]=15.6 for bleeding, NNT=37 for
thromboembolism).5
■ RECOMMENDATIONS FROM
OTHERS
The American College of Chest Physicians
(ACCP) recommends individualizing management
as the optimal frequency of INR monitoring varies
according to patient compliance, dosing decisions,
duration of therapy and changes in health, diet, or
medications.6 The ACCP, the American Heart
Association,7 Micromedex DrugPoints System,8
Goodman and Gilman’s Pharmacological Basis of
Therapeutics,9 and Cecil’s Textbook of Medicine10 all
recommend monthly monitoring once stable. The
Institute for Clinical Systems Improvement’s
Anticoagulation Therapy Supplement Management11
and Managing Oral Anticoagulation Therapy
Clinical and Operation al Guidelines12 also recom-
mend monthly monitoring for stable patients, but
suggest that the interval can be increased to 6
weeks for selected stable patients. 
Linda N. Meurer, MD, MPH, Barbara Jamieson,
